Paxerontine SR Tab. 12.5mg

Ingredient

Paroxetine Hydrochloride

Content

12.5mg

Indication

1) Treatment of major depressive disorder
2) Treatment of panic disorder, with or without agoraphobia
3) Treatment of social anxiety disorder, also known as social phobia
4) Treatment of premenstrual dysphoric disorder (PMDD)

Paxerontine SR Tab. 25mg

Ingredient

Paroxetine Hydrochloride

Content

25mg

Indication

1) Treatment of major depressive disorder
2) Treatment of panic disorder, with or without agoraphobia.
3) Treatment of social anxiety disorder, also known as social phobia.
4) Treatment of premenstrual dysphoric disorder (PMDD).

Pemzayre® tablet 13.5mg

Ingredient

1 Tab(240.0mg) contains, pemigatinib (In-house spec.) 13.5mg

Content

White to off-white round tablet, one side debossed with “I”, the other side with “13.5”.

Indication

The treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after one or more prior line of systemic therapy.

Pemzayre® tablet 9mg

Ingredient

1 Tab(160.0mg) contains, pemigatinib (In-house spec.) 9mg

Content

White to off-white oval tablet, one side debossed with “I”, the other side with “9”.

Indication

The treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after one or more prior line of systemic therapy.

Pemzyre® tablet 4.5mg

Ingredient

1 Tab(80.0mg) contains, pemigatinib (In-house spec.) 4.5mg

Content

White to off-white round tablet, one side debossed with “I”, the other side with “4.5”.

Indication

The treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after one or more prior line of systemic therapy.